05/19/22 1:30 PMNasdaq : GILD Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS ReportGilead Sciences, Inc. today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS. Gilead is also recognized in the report as the number one funder in the U.S. and the number three funder internationally. The report indicates that,“ Private HIV and AIDS...RHEA-AIneutral
05/17/22 4:30 PMNasdaq : GILD Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual MeetingGilead Sciences, Inc. and Kite, a Gilead Company, today announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be...RHEA-AIneutral
05/16/22 4:10 PMNasdaq : GILD FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIVGilead Sciences, Inc. today announced the U.S. Food and Drug Administration has lifted the clinical hold placed on the company’ s Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis. “We are pleased to have identified an alternative vial for lenacapavir, and to now advance the robust...RHEA-AIneutral
05/02/22 8:30 AMNasdaq : GILD Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and InflammationGilead Sciences, Inc. and Dragonfly Therapeutics today announced a collaboration designed to advance a...RHEA-AIpositive
04/28/22 4:02 PMNasdaq : GILD earningsGilead Sciences Announces First Quarter 2022 Financial ResultsGilead Sciences, Inc. announced today its results of operations for the first quarter of 2022.. “Gilead’ s performance in the first quarter reflects the strength and diversity of our business with both our HIV and oncology therapies contributing to year-over-year growth,” said Daniel O’ Day, Chairman and Chief Executive Officer, Gilead Sciences.“ Biktarvy...RHEA-AIneutral
04/26/22 6:13 PMNasdaq : GILD conferencesGilead Sciences to Present at Upcoming Investor ConferencesGilead Sciences, Inc. announced today that its executives will be speaking at the following investor conferences:. Bank of America Healthcare Conference on Tuesday, May 10 at 5:00pm ET. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier...RHEA-AIneutral
04/25/22 2:29 PMNasdaq : GILD covid-19Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for Veklury ® for the treatment of pediatric patients who are older than 28 days, weighing at least 3 kg, and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to...RHEA-AIpositive
04/24/22 6:05 PMNasdaq : GILD covid-19Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19Gilead Sciences, Inc. today announced findings from two studies, which provide further insights on the use of Veklury ® for the treatment of hospitalized and non-hospitalized patients with COVID-19. The first study is a retrospective observational analysis of the real-world treatment data from the Premier Healthcare Database consisting of 853,219...RHEA-AIneutral
04/19/22 8:00 AMNasdaq : GILD fda approvalKite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in MarylandKite, a Gilead Company, today announced the U.S. Food and Drug Administration has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The Maryland site joins Kite’ s existing manufacturing facilities in Southern California and Amsterdam, Netherlands to form the largest, dedicated in-house...RHEA-AIvery positive
04/14/22 4:05 PMNasdaq : GILD earningsGilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022Gilead Sciences, Inc. announced today that its first quarter 2022 financial results will be released on Thursday, April 28, after the market closes. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.RHEA-AIneutral